Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk

Background Tacrolimus (Tac) intraindividual variability (TacIPV) in pediatric kidney transplant patients is only poorly understood. We investigated the impact of TacIPV on de novo donor-specific HLA antibodies ( dn DSA) development and allograft rejection in Caucasian pediatric recipients of a livin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric nephrology (Berlin, West) West), 2022-10, Vol.37 (10), p.2503-2514
Hauptverfasser: Baghai Arassi, Maral, Gauche, Laura, Schmidt, Jeremy, Höcker, Britta, Rieger, Susanne, Süsal, Caner, Tönshoff, Burkhard, Fichtner, Alexander
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Tacrolimus (Tac) intraindividual variability (TacIPV) in pediatric kidney transplant patients is only poorly understood. We investigated the impact of TacIPV on de novo donor-specific HLA antibodies ( dn DSA) development and allograft rejection in Caucasian pediatric recipients of a living or deceased donor kidney with low immunological risk. Methods This was a single-center retrospective study including 48 pediatric kidney transplant recipients. TacIPV was calculated based on coefficient of variation (CV%) 6–12 months posttransplant. TacIPV cutoff was set at the median (25%). Outcome parameters were dn DSA development and rejection episodes. Results In total, 566 Tac levels were measured with median 11.0 (6.0–17.0) measurements per patient. The cutoff of 25% corresponded to the median CV% in our study cohort (25%, IQR 18–35%) and was comparable to cutoffs determined by receiver operating characteristic (ROC) curve analysis. High TacIPV was associated with higher risk of dn DSA development (HR 3.4, 95% CI 1.0–11.1, P  = 0.047; Kaplan–Meier analysis P  = 0.018) and any kind of rejection episodes (HR 4.1, 95% CI 1.1–14.8, P  = 0.033; Kaplan–Meier analysis P  = 0.010). There was a clear trend towards higher TacIPV below the age of 6 years. TacIPV (CV%) was stable over time. A TacIPV (CV%) cutoff of 30% or IPV quantification by mean absolute deviation (MAD) showed comparable results. Conclusions High TacIPV is associated with an increased risk of dn DSA development and rejection episodes > year 1 posttransplant even in patients with low immunological risk profile. Therefore, in patients with high TacIPV, potential causes should be addressed, and if not resolved, changes in immunosuppressive therapy should be considered. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information .
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-022-05426-3